U.S. Food and Staples Retail Stock News

NasdaqGS:DSP
NasdaqGS:DSPSoftware

Viant Technology (DSP) Is Down 11.2% After Q1 Loss Narrows And Q2 Outlook Emerges - What's Changed

In May 2026, Viant Technology Inc. reported past first-quarter 2026 results, with sales rising to US$88.54 million and its net loss narrowing to US$0.46 million, while also posting a reduced basic and diluted loss per share of US$0.03 from continuing operations. On the same day, the company issued second-quarter 2026 revenue guidance of US$98.5 million to US$101.5 million, giving investors fresh visibility into near-term demand after a period of higher sales and a smaller loss. We’ll now...
NasdaqCM:INVE
NasdaqCM:INVEElectronic

Identiv (INVE) Q1 Loss Of US$3.7 Million Tests Bullish Growth Narrative

Identiv (INVE) opened 2026 with Q1 revenue of US$7.4 million and a reported loss of US$3.7 million, equal to an EPS loss of US$0.15. This sets a clear benchmark for how the year is starting after a period of steady revenue contributions but continued losses. The company has seen quarterly revenue move from US$5.3 million in Q1 2025 to US$7.4 million in Q1 2026, while quarterly EPS has stayed in loss-making territory between US$0.15 and US$0.26 over that span. For investors, the key question...
NYSE:IT
NYSE:ITIT

Gartner Lawsuit And AI Research Challenge Test Investor Confidence And Valuation

A class action lawsuit has been filed against Gartner (NYSE:IT) alleging misleading statements about contract value growth and Consulting segment revenue projections. The case focuses on whether prior disclosures accurately reflected business trends and carries a legal deadline for affected shareholders to respond. The lawsuit coincides with a material share price impact, with the stock down 10.9% over the past week and 40.7% year to date, closing at $140.65. In parallel, new Gartner AI...
NYSE:IIPR
NYSE:IIPRIndustrial REITs

Cannabis Tax Shift Puts Tenant Health And Growth In Focus For IIPR

U.S. federal cannabis rescheduling is being considered, which could remove Section 280E tax burdens for qualifying marijuana operators. This change would allow many cannabis businesses to deduct normal operating expenses for federal tax purposes. Innovative Industrial Properties (NYSE:IIPR) could see meaningful second order effects as tenants potentially gain financial flexibility. For investors watching NYSE:IIPR at around $54.84, the tax conversation is not just a policy story; it goes...
NYSE:USB
NYSE:USBBanks

U.S. Bancorp Amazon Card Partnership And What It Could Mean For USB

U.S. Bancorp (NYSE:USB) and Amazon have introduced new co-branded Prime Business Card and Amazon Business Card products. The launch expands their existing relationships with Amazon and Mastercard into a wider suite of business credit solutions. The cards are aimed at business customers seeking rewards, flexible financing options, and spend management tools for Amazon-related purchases. For U.S. Bancorp, this move sits at the intersection of commercial banking and business payments, an area...
NasdaqGS:MORN
NasdaqGS:MORNCapital Markets

Is It Time To Reassess Morningstar (MORN) After A 46% One Year Share Price Slide

If you are wondering whether Morningstar stock now offers value after a rough patch, starting with a clear look at price versus fundamentals can help frame your next move. The stock closed at US$166.05, with the share price declining 6.7% over the past week, 3.6% over the past month, 21.1% year to date, and 46.0% over the past year, which can change how investors think about both risk and opportunity. Recent coverage has focused on how market sentiment toward Morningstar has shifted, as...
NasdaqGM:CRMD
NasdaqGM:CRMDPharmaceuticals

CorMedix (CRMD) Q1 Earnings Margin Surge Tests Bearish Narratives

CorMedix (CRMD) has opened 2026 with Q1 revenue of US$127.4 million and basic EPS of US$0.49, set against a very large year over year earnings expansion and a move in net profit margin from 20.8% to 45% over the past 12 months. The company has seen quarterly revenue step up from US$39.1 million in Q1 2025 to US$127.4 million in Q1 2026. Trailing twelve month EPS has moved from US$0.28 at the start of 2025 to US$2.38 by Q1 2026. This gives investors a results set where wider margins and higher...
NasdaqGM:FATE
NasdaqGM:FATEBiotechs

Fate Therapeutics (FATE) Q1 Losses Reinforce Concerns Over Rich 35.1x P/S Valuation

Fate Therapeutics (FATE) opened 2026 with Q1 results showing revenue of about US$1.3 million and a basic EPS loss of US$0.26, alongside a net loss of US$31.2 million. Over recent quarters the company has seen quarterly revenue sit in a tight band around US$1.3 million to US$1.9 million, while basic EPS losses have moved between roughly US$0.26 and US$0.44 and trailing twelve month EPS has been around a US$1.09 loss. With the stock trading near US$1.90, the key question for investors is...
NYSE:BLSH
NYSE:BLSHCapital Markets

Bullish (BLSH) Q1 Loss Of US$581.7 Million Tests Growth Focused Narratives

Bullish (BLSH) opened 2026 with Q1 revenue of US$77.5 million, a basic EPS loss of US$3.85, and a net loss of US$581.7 million, setting a tough but clear baseline for investors watching how the story develops from here. Over the past year, the company has seen quarterly revenue move from US$39.3 million in Q4 2024 to US$77.5 million in Q1 2026, while EPS has swung between a profit of US$1.39 and losses such as US$3.85, highlighting how quickly margins can shift as the business scales. With...
NasdaqGS:COO
NasdaqGS:COOMedical Equipment

New Cooper Companies Director Adds Oversight As Shares Trade Below Targets

Cooper Companies (NasdaqGS:COO) has appointed Paul Keel to its Board of Directors. Keel will also serve on the Board’s Audit Committee. The appointment brings experience from senior executive roles at major medical technology and industrial companies. For investors watching Cooper Companies at a share price of $60.38, this board change comes after a period of weak stock performance. The stock is down 15.7% over the past 30 days, 25.6% year to date, and 25.9% over the past year, with a 37.9%...
NasdaqCM:SSII
NasdaqCM:SSIIMedical Equipment

SS Innovations International (SSII) Losses Challenge Bullish Narratives After Q1 2026 Results

SS Innovations International (NasdaqCM:SSII) opened 2026 with Q1 revenue of about US$11.1 million and a basic EPS loss of US$0.02, while trailing 12 month figures show revenue of roughly US$48.5 million and a basic EPS loss of US$0.05. Over the past reported quarters, revenue has ranged from about US$5.1 million in Q1 2025 to US$14.5 million in Q4 2025, with basic EPS losses moving between roughly US$0.00 and US$0.03 per share. Investors are therefore likely to focus on how efficiently that...
NasdaqGM:KROS
NasdaqGM:KROSBiotechs

Keros Therapeutics (KROS) Revenue Collapse To US$0.4 Million Challenges Bullish Growth Narratives

Keros Therapeutics (KROS) has just posted Q1 2026 results, with revenue of US$0.4 million, a basic EPS loss of US$1.21 and a net loss of US$23.7 million, setting the tone for the quarter at a share price of US$10.99. The company has seen quarterly revenue move from US$211.2 million in Q1 2025 to US$0.4 million in Q1 2026, while basic EPS shifted from a profit of US$3.66 to a loss of US$1.21. This puts the spotlight on how changes in revenue expectations and potential margin developments could...
NYSE:BNT
NYSE:BNTInsurance

Brookfield Wealth Solutions (BNT) Q1 Loss And Margin Compression Challenge Bullish Earnings Narrative

Brookfield Wealth Solutions (BNT) has opened 2026 with a mixed Q1 print, reporting revenue of US$1.7b and a loss per share of US$1.83 on net income of US$609m. Over the last few quarters, revenue has moved from US$2.6b in Q1 2025 to US$3.1b in Q4 2025 before landing at US$1.7b in Q1 2026. Basic EPS has swung from a loss of US$0.90 to a profit of US$1.89 and US$1.18, then just US$0.02 ahead of the latest quarterly loss. With trailing 12 month EPS of US$1.45 and a net profit margin that has...
NYSEAM:NINE
NYSEAM:NINEEnergy Services

Nine Energy Service (NINE) Profit Swing To US$1.95 EPS Tests Cash Flow Bear Thesis

Nine Energy Service (NINE) has put up a sharp swing into profit in Q1 2026, with revenue of US$130.0 million and net income of US$106.6 million translating into basic EPS of US$1.95 for the quarter. Over the past five quarters, revenue has moved from US$150.5 million in Q1 2025 through a range of US$132.2 million to US$147.3 million, while EPS has shifted from a loss of US$0.18 per share in Q1 2025 to a profit of US$1.95 in Q1 2026. This sets up a story where margins rather than top line are...
NasdaqGM:ASTL
NasdaqGM:ASTLMetals and Mining

Algoma Steel Group Q1 Loss Narrows Yet Deep Trailing Losses Challenge Bullish Narratives

Algoma Steel Group’s Q1 2026 Results: Revenue Slides While Losses Narrow Algoma Steel Group (NasdaqGM:ASTL) opened fiscal 2026 with Q1 revenue of C$296.9 million and a basic EPS loss of C$1.46 per share, compared with a loss of C$0.61 per share in Q4 2024 on revenue of C$590.3 million. Over the past year, quarterly revenue has moved from C$517.1 million in Q1 2025 to C$296.9 million in Q1 2026, while net losses widened from C$24.5 million to C$159.4 million, setting a tough backdrop for the...
NasdaqCM:MDXH
NasdaqCM:MDXHBiotechs

MDxHealth (MDXH) Q1 Loss Near US$8.9 Million Reinforces Bearish Profitability Concerns

MDxHealth (NasdaqCM:MDXH) opened Q1 2026 with revenue of US$27.4 million and a basic EPS loss of US$0.17, alongside trailing 12 month revenue of US$111.0 million and a cumulative net loss of US$33.2 million that keeps the focus firmly on profitability. Over the last year, the company has seen revenue move from US$24.7 million in Q4 2024 to US$27.4 million in Q1 2026, while quarterly EPS has stayed in a tight range between a loss of US$0.14 and US$0.19, highlighting a situation where top line...
NasdaqGS:MGNX
NasdaqGS:MGNXBiotechs

MacroGenics (MGNX) Quarterly Loss Of US$36.8 Million Tests Bullish Path To Profitability

MacroGenics (MGNX) has opened Q1 2026 with revenue of about US$20.8 million and a basic EPS loss of roughly US$0.58, while trailing twelve month figures sit at revenue of about US$157.1 million and a basic EPS loss of around US$1.11. Over recent quarters, the company has reported revenue between US$13.2 million and US$72.8 million, with quarterly EPS ranging from a profit of about US$0.27 to losses such as US$0.65. This update keeps the focus on how the company is scaling revenue relative to...
NasdaqGS:HFWA
NasdaqGS:HFWABanks

Is Heritage Financial (HFWA) Pricing Looked At Differently After Recent Regional Bank Headlines?

Wondering whether Heritage Financial at around US$26.48 is offering genuine value or just looks reasonably priced on the surface? This article focuses on what the current share price might be implying about the company. The stock has slipped around 3.4% over the past week and 2.4% over the past month, yet it is still up 11.7% year to date and 13.4% over the past year, with a 3 year return of 85.0% and a 5 year return of 12.8%. Recent news coverage around regional banks has put more attention...
NasdaqCM:VRCA
NasdaqCM:VRCAPharmaceuticals

Verrica Pharmaceuticals (VRCA) Returns To Larger Q1 Loss Challenging Bullish Profitability Narratives

Verrica Pharmaceuticals (VRCA) opened Q1 2026 with revenue of about US$5.0 million and a basic EPS loss of US$0.45, while trailing twelve month figures show revenue of US$37.2 million and a basic EPS loss of US$1.31. Over the past year, the company reported quarterly revenue moving from US$3.4 million in Q1 2025 to US$14.3 million in Q3 2025, then settling around the US$5.0 million mark in Q1 2026. EPS moved from a loss of US$1.03 to a small profit of US$0.02 in Q2 2025 before returning to...
NYSE:PSFE
NYSE:PSFEDiversified Financial

Paysafe (PSFE) Q1 Loss Deepens And Tests Bulls On Turnaround Narrative

Paysafe (PSFE) opened 2026 with Q1 revenue of US$442.7 million and a loss of US$36.5 million on a net income basis, which translated to basic EPS of a US$0.71 loss. Over the past five quarters, the company has seen revenue move from US$420.1 million in Q4 2024 to US$401 million in Q1 2025 and then to US$442.7 million in Q1 2026. Over the same period, basic EPS shifted from a profit of US$0.55 in Q4 2024 to losses of US$0.33 in Q1 2025 and US$0.71 in Q1 2026. For investors, the latest report...
NYSEAM:ESP
NYSEAM:ESPElectrical

Espey Mfg. & Electronics (ESP) Non Cash Heavy 25.5% Margin Challenges Bullish Earnings Narratives

Espey Mfg. & Electronics (ESP) has reported another solid set of Q3 2026 numbers, with revenue of about US$11.4 million and basic EPS of roughly US$1.03, supported by trailing 12 month EPS of US$3.95 on revenue of around US$42.2 million. The company has seen quarterly revenue range between US$9.1 million and US$13.6 million over the past six periods, while basic EPS has moved between US$0.66 and US$1.10. This sets up the latest quarter against a backdrop of higher trailing earnings growth and...
NasdaqGS:MXCT
NasdaqGS:MXCTLife Sciences

MaxCyte (MXCT) EPS Loss Narrows In Q1 2026 Challenging Bearish Profitability Narratives

MaxCyte (NasdaqGS:MXCT) opened Q1 2026 with revenue of US$9.7 million and a basic EPS loss of US$0.04, while trailing 12 month figures show revenue of US$32.3 million and a basic EPS loss of US$0.37. The company has seen quarterly revenue move from US$10.4 million in Q1 2025 to US$9.7 million in Q1 2026, with net income moving from a loss of US$10.3 million to a loss of US$4.8 million over the same period. These figures frame the discussion for investors who are focused on how margins develop...
NasdaqGS:SNPS
NasdaqGS:SNPSSoftware

Profitable AI Stocks One Debt Free Earner One Quiet Chip Powerhouse

AI spending is no longer just a race to build the biggest models; it is increasingly about which companies can turn that investment into real earnings. With inflation pressures touching everything from fuel to freight, and central banks keeping rates higher for longer, cash generation and pricing power matter more than ever. The Profitable AI Stocks screener focuses on businesses already using AI to support profits rather than just promises. This article highlights 3 stocks from that list...
NasdaqCM:PAYS
NasdaqCM:PAYSDiversified Financial

Is Paysign’s (PAYS) Affordability Shift Redefining Its Core Profit Engine?

Paysign, Inc. reported past first-quarter 2026 results on May 12, posting revenue of US$28.04 million and net income of US$5.44 million, with diluted EPS of US$0.09 from continuing operations. The quarter marked a shift as patient affordability programs became Paysign’s largest revenue contributor, reflecting a mix change toward higher-margin pharma offerings. We’ll now examine how this record first quarter and the rise of patient affordability as Paysign’s largest revenue stream affect its...